GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Erste Group Plans Tender Offer to Boost Poland Bank Stake 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
US Stock Futures Fall as Treasury Yields Surge Ahead of Trump-Xi Summit 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
Japanese Yen Rebounds as Trump Flags Currency Weakness 
Jeff Bezos Invests $32 Billion in Blue Origin as Space Firm Targets Major Growth 
China’s ‘Lipstick King’ Says AI Won’t Replace Livestream Hosts 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks 
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Add as a preferred source on Google
Samsung Biologics, South Korea's biotech behemoth, expands its portfolio in a $1.08 billion deal with U.S. pharma titan, Pfizer, marking a landmark in global biotech manufacturing. The enhanced partnership will leverage Samsung's newest facility to produce Pfizer's multiproduct biosimilar portfolio.
This includes a new contract signed with Pfizer, building upon the initial deal established in March. Under the new agreement, Samsung Biologics will manufacture an additional $193 million of Pfizer products.
Additionally, Samsung Biologics will produce Pfizer's multiproduct biosimilar portfolio, encompassing oncology, inflammation, and immunotherapy, with a value of $704 million. The company will extend its manufacturing capabilities to provide Pfizer ample capacity for large-scale production of a multiproduct biosimilar portfolio.
This strategic collaboration will occur at Samsung Biologics' newest facility, Plant 4, in Songdo, South Korea. Completing the 240,000-liter biomanufacturing plant in June 2023 marks a significant milestone in the continued growth of Samsung Biologics.
Mike McDermott, Chief Global Supply Officer and Executive Vice President at Pfizer, expressed his enthusiasm for the partnership, stating they are pleased to extend the strategic collaboration with Pfizer as we share and support their strong vision to bring innovative solutions for patients around the globe.
These manufacturing partnerships solidify Samsung Biologics' position in the global contract development and manufacturing organization (CDMO) market. As part of its expansion strategy, the company is increasing its production capacity and aims to become a major player in the industry.
The contracts with Pfizer highlight the long-term strategic partnership between the two companies, further establishing Samsung Biologics as a trusted collaborator. The company plans to explore new avenues in overseas markets by considering opening new sales offices to facilitate communication with global customers. With an existing office in New Jersey and a research and development center in San Francisco, Samsung Biologics is set for continued growth on a global scale.
